Deep-pocketed investors have adopted a bullish approach towards Sarepta Therapeutics (NASDAQ:SRPT), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Reddit Inc (Symbol: RDDT), where a total volume of 36,071 contracts has been ...

CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after ...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.

CAMBRIDGE, Mass. -- (BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p ...

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny July 22, 2025 — 09:33 am EDT Written by Zacks Equity Research for Zacks -> ...

(RTTNews) - Sarepta Therapeutics, Inc. (SRPT), Friday acknowledged the Committee for Medicinal Products for Human Use's negative opinion on the conditional marketing authorization for ELEVIDYS in ...

Sarepta Therapeutics (SRPT) is down more than -9% after an evaluation committee of the European Medicines Agency recommended against the approval of the company’s gene therapy Elevidys.

Sarepta Therapeutics (SRPT) is down more than -5% after an evaluation committee of the European Medicines Agency recommended against the approval of the company’s gene therapy Elevidys.

Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.

Sarepta Therapeutics (SRPT) is down more than -14% after it said another patient died from acute liver failure after receiving one of its experimental gene therapies for a muscle disease.